Compare Dropbox Inc (DBX) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dropbox Inc vs Merck & Co., Inc. — how do they compare? Dropbox Inc trades at $34.36 (market cap $7.42B), while Merck & Co., Inc. trades at $144.66 (market cap $351.28B). The key difference: Merck & Co., Inc. is far larger — about 47.3× Dropbox Inc's market cap, and Merck & Co., Inc. pays a 2.39% dividend while Dropbox Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Dropbox Inc for 97 Days and Merck & Co., Inc. for 98 Days on average.
| DBX | MRK | |
|---|---|---|
Market Cap | $7.42B | $351.28B |
Volume | 3,061,580 | 7,969,665 |
Sector | Technology | Health |
52-Week High | $37.74 | $156.43 |
52-Week Low | $22.06 | $82.49 |
Typical Hold Time | 97 Days | 98 Days |
Enterprise Value | $10.29B | $398.04B |
Dividend Yield | — | 2.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dropbox (DBX) trades at $33.08, down 1.93% amid bearish technical signals and mixed analyst sentiment. The company maintains strong profitability with 79.72% gross margins and has beaten earnings estimates for three consecutive quarters. However, negative shareholder equity and recent insider selling create headwinds. Technical indicators show bearish momentum with support at $32 and resistance at $34.
Outlook remains cautious despite solid fundamentals. The stock faces valuation concerns with a P/E of 18.86 and mixed analyst ratings (37.5% buy, 31.25% hold/sell each). Key risks include stagnant revenue growth, high debt levels, and competitive pressures in cloud storage. The consensus price target of $26.83 suggests potential downside from current levels.
Merck (MRK) trades at $142.79, up 0.61% on the day, with a bearish technical signal despite beating earnings estimates in recent quarters. The company reported 2025 revenue of $65.01B and net income of $18.25B, with a high P/E ratio of 113.9 reflecting premium valuation. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, while institutional investors have been increasing stakes.
The outlook is mixed: strong analyst consensus (68% buy ratings) and a $158.78 price target suggest upside, but high valuation and bearish technicals pose near-term risks. Key opportunities include pipeline expansion via M&A; risks involve integration challenges and patent pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dropbox Inc
Dropbox is a leading provider of cloud-storage and content collaboration tools with an emphasis on individuals and SMB. The company was founded in 2007 and was a pioneer in cloud storage and cross-platform file syncing. Utilizing inorganic and organic means, the firm has been working on diversifying its product mix and pivoting away from the cloud-storage space.
Read more on DBX →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
